Table II.
Variable | Group | No. of patients | % of positive samples | M (%) | C (%) | M + C (%) | N (%) |
---|---|---|---|---|---|---|---|
β-catenin | C | 8 | 100 | 75 | 25 | 0 | 0 |
CH-C | 54 | 96 | 31 | 44 | 25 | 0 | |
HCC | 61 | 92 | 60 | 13 | 22 | 5 | |
E-cadherin | C | 7 | 100** | 86 | 0 | 14 | 0 |
CH-C | 41 | 83* | 56 | 18 | 26 | 0 | |
HCC | 60 | 58 | 77 | 14 | 9 | 0 | |
N-cadherin | C | 8 | 50$,$$ | 100 | 0 | 0 | 0 |
CH-C | 28 | 7 | 0 | 100 | 0 | 0 | |
HCC | 59 | 17 | 40 | 0 | 60 | 0 |
M – membranous, C – cytoplasmic, M + C – membranous/cytoplasmic, N – nuclear pattern of IHC reaction;
p < 0.05 between E-cadherin expression in CH-C and HCC
p < 0.01 between E-cadherin expression in control and HCC;
p < 0.05 between N-cadherin expression in control and HCC
p < 0.01 between N-cadherin expression in control and CH-C.